FDA Approves ORLADEYO Oral Pellet Formulation

BioCryst Pharmaceuticals has received FDA approval for an oral pellet formulation of ORLADEYO for hereditary angioedema prophylaxis in adults and adolescents, according to Simplywall. The approval adds another oral formulation to the company’s ORLADEYO offering.

FDA decision adds oral pellet formulation

Simplywall reported that the newly approved ORLADEYO oral pellet formulation is indicated for prophylaxis of hereditary angioedema in adults and adolescents. The publisher described the formulation as a second oral option alongside the existing ORLADEYO capsule.

The FDA action is centered on formulation availability for the product’s reported prophylaxis use. For pharmaceutical and biotech sales professionals, the news creates a clear product-update discussion: ORLADEYO now includes an oral pellet formulation in addition to the existing capsule, according to Simplywall.

Key details for field conversations

Product discussions should distinguish the newly approved oral pellet formulation from the existing capsule while remaining consistent with FDA-approved product information. Simplywall’s report identifies hereditary angioedema prophylaxis as the relevant use and adults and adolescents as the reported patient population.

• BioCryst Pharmaceuticals received FDA approval, according to Simplywall.
• The approved product update is an oral pellet formulation of ORLADEYO.
• Simplywall reported the formulation for hereditary angioedema prophylaxis in adults and adolescents.
• The oral pellet formulation joins the existing ORLADEYO capsule as an oral option.

Market activity reported by Simplywall

Simplywall also reported BioCryst’s share price at US$8.10. The publisher cited a 1-day share price return of 2.79% and a 7-day share price return of 2.02%. It also reported share price declines of 5.70% over the last 30 days and 15.01% over the last 90 days.

For sales teams following the event, the central development remains the FDA approval of the ORLADEYO oral pellet formulation. The available report supports discussion of the new formulation, its reported prophylaxis use, and its position alongside the existing capsule.

Source: Simplywall.